Johnson & Johnson (NYSE:JNJ) today announced results from the final analysis of the Phase 3 PROTEUS study showing the investigational use of apalutamide plus hormone therapy (androgen deprivation ...
Compared with patients receiving hormone therapy alone, patients were nine times more likely to have little to no cancer remaining in the prostate after surgery, with a 20 percent reduction in the ris ...
Johnson & Johnson's Erleada drug, combined with hormone therapy, significantly reduces the risk of prostate cancer spread and ...
Johnson & Johnson’s PROTEUS Phase 3 trial shows apalutamide + hormone therapy before/after surgery improves outcomes in ...
Johnson & Johnson's prostate cancer drug Erleada, reportedly used alongside standard home-blocking therapy before and after ...
Israeli Prime Minister Benjamin Netanyahu was taken to a Jerusalem hospital for dental treatment, reigniting focus on his ...
In a randomized clinical trial, Mass General Brigham researchers found testosterone replacement therapy also improved quality of life for men who had undergone radical prostatectomy ...
Israeli PM Benjamin Netanyahu was taken to a Jerusalem hospital months after revealing prostate cancer treatment. Here’s what ...
Thousands of men with advanced prostate cancer could soon live longer thanks to a treatment which cuts the risk of the disease returning by nearly a third.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results